Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Poolbeg Pharma Ltd. ( (GB:POLB) ) just unveiled an update.
Poolbeg Pharma reported significant advancements in 2025, culminating in a successful fundraise and strategic preparations for upcoming clinical trials in 2026. Key developments include progress with POLB 001, central to a multi-centre TOPICAL trial addressing CRS in cancer immunotherapy, and an innovative obesity therapy program. Positioned as a leader in cancer immunotherapy solutions and leveraging substantial funding, Poolbeg is preparing for major clinical milestones and partnerships, enhancing its market potential and opportunities in healthcare innovation.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company primarily focused on advancing the field of cancer immunotherapy. Its flagship product, POLB 001, aims to significantly improve the safety and accessibility of cancer immunotherapies by preventing the life-threatening side effect known as Cytokine Release Syndrome (CRS). The company is also exploring an oral GLP-1 therapy for obesity, reflecting its commitment to addressing large markets and unmet medical needs.
Average Trading Volume: 1,100,949
Technical Sentiment Signal: Hold
Current Market Cap: £26.84M
Find detailed analytics on POLB stock on TipRanks’ Stock Analysis page.